// App-Quantinova.ai

Mo1794 : Delayed Response to Golimumab Therapy: UC Patient Characteristics and Long-term Clinical Outcome: Post-Hoc Analyses From the PURSUIT Program

Researchers

Presenter

  • Walter Reinisch

Principal Investigators

  • Peter R. Gibson

  • Colleen Marano

  • William Sandborn

  • Brian G. Feagan

  • Stephen Xu

  • Rick Strauss

  • Hongyan Zhang

  • Dino Tarabar

  • Zbigniew Hebzda

  • Paul J. Rutgeerts

Medical Centers

  • Universitatsklinik fur Innere Medizin III/McMaster University, Hamilton, Ontario, Canada

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Military Medical Academy, Belgrade, Serbia

  • University of California, San Francisco, San Francisco, California, United States

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Military Hospital, Wroclaw, Poland

  • Alfred Hospital, Melbourne, Victoria, Australia

  • Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

Locations

  • Canada

  • Poland

  • Australia

  • United States

  • Serbia

  • Belgium

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • C reactive protein

  • Fas receptor

Drug/Treatment

  • golimumab

Outcome

  • Unknown

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved